Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Precocious Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Central Precocious Puberty (CPP)
Interventions
Leuprolide Acetate (LA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced May 22, 2026, 12:45 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia (CAH), Familial Male-Limited Precocious Puberty (FMPP)
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 99 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
Interventions
Leuprolide Acetate 3 Month Depot
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Precocious Puberty, Central
Interventions
Leuprolide Acetate 45 mg
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
2 Years to 9 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced May 22, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Hypogonadism, Precocious Puberty
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
7 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1993
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 12:45 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Genetic Disorder, Infertility, Hypogonadism, Amenorrhea
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Weeks to 120 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Lupron (leuprolide acetate)
Drug
Lead sponsor
Abbott
Industry
Eligibility
Up to 10 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced May 22, 2026, 12:45 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Hypogonadism, Hypergonadism, Precocious Puberty, Late Puberty, Amenorrhea
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Puberty, Precocious, McCune-Albright Syndrome
Interventions
Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Miami, Florida • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced May 22, 2026, 12:45 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Kallmann Syndrome, Puberty, Delayed, Puberty, Precocious, GnRH Deficiency
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
4,042 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions
Paliperidone ER
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
14
States / cities
Cerritos, California • San Diego, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Precocious Puberty
Interventions
Spironolactone, Testolactone, Deslorelin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia, Precocious Puberty
Interventions
Letrozole
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
1 Year to 8 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 12:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Delayed Puberty, Precocious Puberty
Interventions
Leuprolide Acetate - Early Puberty Leuprolide Visit, Ganirelix - Early Puberty Ganirelix Visit, Ganirelix - Delayed Puberty Ganirelix Visit, Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Drug
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Central Precocious Puberty
Interventions
Triptorelin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
2 Years to 9 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced May 22, 2026, 12:45 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Puberty; Precocious, Central
Interventions
Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
2 Years to 9 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced May 22, 2026, 12:45 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Central Precocious Puberty
Interventions
Debio 4326
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
5 Years to 8 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Polyostotic Fibrous Dysplasia, Precocious Puberty
Interventions
Testolactone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1982 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 12:45 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Central Precocious Puberty
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
3 Years to 9 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Minneapolis, Minnesota • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced May 22, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Bicalutamide, Anastrozole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 13 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Jacksonville, Florida • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced May 22, 2026, 12:45 AM EDT